Friulimicin B

Drug Profile

Friulimicin B

Alternative Names: Friulimicin; Friulimycin B; Lipopeptide - Merlion Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis Pharmaceuticals
  • Developer MerLion Pharmaceuticals
  • Class Antibacterials; Lipopeptides
  • Mechanism of Action Bacterial polysaccharide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Nosocomial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Nosocomial-infections in Singapore (Topical)
  • 05 Jan 2011 Friulimicin B is available for licensing as of 05 Jan 2011.
  • 05 Jan 2011 Preclinical trials in Nosocomial infections in Singapore (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top